Editorial

499 Immersive medical virtual reality: still a novelty or already a necessity?
T. Lentscher, A M Barnett, M Billinghurst, B Lange

Multiple sclerosis

502 Spinal cord reserve in multiple sclerosis
J Sastre-Garriga, A Revira, A Garràs-Vidal, P Carbetta-Martínbet, M Alberich, A Vidal-Jordana, C Auger, M Timoteo, X Montalban, D Pareto

511 Multiple sclerosis mortality in New Zealand: a nationwide prospective study
R Leadbetter, M Mackay, D J Myall, B V Taylor, P Joshi, NZMSPS group, D F Mason

518 Gene–environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures

526 Gene determined serum serine level has a novel causal effect on multiple sclerosis risk and predicts disability progression

Neuro-inflammation

550 Molecules of senescent glial cells differentiate Alzheimer’s disease from ageing
L Dai, F Gao, Q Wang, X Lü, Z Cheng, Y Wu, X Chai, H Zetterberg, K Blennow, A I Levey, J Shi, Y Shen, On behalf of CANDI Consortium

Neurodegeneration

532 Prognostic biomarkers in prodromal α-synucleinopathies: DAT binding and REM sleep without atonia
D Kuntz, S Stots, J de Zecew, A Papakonstantinou, S Dünchen, M Halbericht, M Pleckin, F Bes

Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration

Disclaimer:
The Editor of JNNP has been granted editorial freedom and JNNP is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. JNNP is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded from the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by JNNP does not imply endorsement. BMJ Publishing Group Limited shall not be liable for any loss, injury or damage however arising from JNNP (except for liability which cannot be legally excluded).

Copyright: © 2023 BMJ Publishing Group Ltd. All rights reserved: no part of this publication may be reproduced in any form without permission.

ISSN: 0022-3050 (print)

ISSN: 1468-330X (online)

Impact factor: 13.654

This article has been chosen by the Editor to be of special interest and is freely available online.

This article has been chosen in conjunction with the BMJ Patient Forum to be of particular interest to patients and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

The article is part of the Impact Commentaries series.

The online version of this article contains multiple choice questions hosted on BMJ Learning.
Cerebrovascular disease
567  Long-term outcomes of moyamoya disease versus atherosclerosis-associated moyamoya vasculopathy using high-resolution MR vessel wall imaging  
M Lu, H Zhang, S Liu, D Liu, P Peng, F Hao, F Yuan, Y Liu, F Sheng, J Zheng, X Zhao, Y He, C Han, J Cai

Neurosurgery
575  Adverse events associated with microsurgical treatment for ruptured intracerebral aneurysms: a prospective nationwide study on subarachnoid haemorrhage in Sweden  

Occasional essay
581  Isolated rapid eye movement sleep behaviour disorder: clinical and research implications  
A Stefani, C Trenkwalder, I Arnulf, D J Blwise, B F Boeve, Y Inoue, A Iranzo, S JG Lewis, F Provini, C Schenck, G K Wenning, Y Kwok Wing, B Hogl, A Videnovic

PostScript
583  Letters